No abstract

From the perspective of private paying source, the projection is that adding saxagliptine with MF save costs when compared with the addition of rosiglitazone or pioglitazone in patients with DM2 that have not reached the HbA1c goal with metformin monotherapy. The BIM of including saxagliptine in the reimbursement lists of health plans indicated significant savings on the three-year horizon.

A147patient population. Based on a representative population-based patient-cohort, the objective of this study was to develop a decision model that could reflect realworld practice and predict the costs throughout treatment pathway. Methods: All patients newly diagnosed with FL in the UK's population-based Haematological Malignancy Research Network (www.hmrn.org) between 2004 and 2011 were followed until 2014 (n= 741). The mapped treatment pathways, alongside cost information derived from the National Tariff 2013/14, were incorporated into a discrete event simulation in order to reflect the heterogeneity of clinical characteristics, such as stage, and treatment options. Results: The annual cost of treating FL across the UK (population ~ 64 million) was estimated to be around £17 million. The predicted mean cost per patient from diagnosis to death was £10,202. Based on the initial treatment decision average costs were; £17,054 for those treated with chemotherapy (46%), £4,651 for those treated with radiotherapy (12%), and £2,185 for those managed by "watch-and-wait" (42%). The model's predicted costs per patient captured 95% of the actual costs calculated from empirical data, supporting the validity of the model. ConClusions: This is the first modelling study using 'real world' evidence to predict costs of entire FL treatment pathways. As several expensive new technologies/treatments for FL are on the horizon, future application of the model developed here could be used to assess their economic impacts and support healthcare decision makers, especially in the era of personalised medicine.

High-volume hospital was the strongest predictor for shorter LoS, whereas SRC certification was the strongest predictor of lower ICU need. Public health policies targeting an increase of efficiency and patient access to the procedure should take into account these results.

Cost per responder analysis of biologic drugs for the treatment of moderate to severe psoriasis under Brazilian public and private healthcare systems perspectives

RESUMOObjetivos: Avaliar o impacto econômico do mieloma múltiplo (MM) no sistema privado de saúde brasileiro. Métodos: A base de dados Orizon, uma base administrativa para fins de reembolso contendo dados de pacientes que realizaram procedimentos médicos em ambiente hospitalizar e ambulatorial, foi analisada retrospectivamente de jan./2013 a ago./2016. A base incluiu pacientes que foram diagnosticados com MM (CID-10 C90.0) durante o período de tempo mencionado e todos os procedimentos subsequentes realizados pelo paciente após o diagnóstico. Foram utilizados como critério de elegibilidade pacientes com MM tratados entre jan./2013 e jun./2015, com acompanhamento de pelo menos 365 dias, tendo pelo menos um registro durante esse período. Os desfechos foram expressos em custos médicos diretos (CMD) por paciente/ano, calculados como a soma dos gastos médicos por paciente divididos por pacientes-ano, por um período máximo de 12 meses. Os CMDs foram categorizados em exames, procedimentos, medicamentos (incluindo quimioterapia e outros tratamentos) e outros custos (materiais, gases medicinais, pacotes e taxas diversas). Foram conduzidas análises adicionais para quimioterapia e internações. Resultados: Dos 1.332 pacientes com MM, 973 atenderam ao critério de elegibilidade, sendo incluídos na análise. O CMD total foi de R$ 124.144 por paciente-ano, do qual R$ 66.757 (54%) são relacionados a medicamentos, R$ 45.474 (37%) a internações e R$ 11.912 (10%) a outros custos ambulatoriais. Um total de 3.050 internações foi identificado em 741 (76%) pacientes, com custo médio de R$ 23.151 por internação. Conclusões: O tratamento do MM representa impacto econômico significativo para operadoras de saúde. Custos de medicamentos e internações representam 90% do custo total. ABSTRACT Objectives:To evaluate the economic impact of multiple myeloma (MM) in the Brazilian private health care system. Methods: The Orizon database, an administrative claims database containing inpatient and outpatient data, was retrospectively analyzed from Jan/2013 to Aug/2016. The database included patients who had been diagnosed with MM (ICD-10 C90.0) during the aforementioned timeframe and all subsequent procedures performed by the patient after the diagnosis. Eligibility criteria were patients with MM (ICD-10 code C90.0) treated between Jan/2013 and Jun/2015, who were followed by at least 365 days (1 year) and had at least one claim during this period. Outcome was direct medical costs (DMC) per patient-year, calculated as the sum of the medical claims for each patient included in the analysis divided by total patient-years, for a maximum period of 12-months. DMC was categorized in exams, procedures, medications (including chemotherapy and other medications) and other cost (materials, medicinal gases, packages and others costs). Further analysis was conducted for chemotherapy and hospitalizations. Results: From 1,332 patients with MM identified in the database, 973 met the eligibility criteria and were included in the analysis. Total DMC in this population ...

No abstract

was estimated taking as a dependent variable the formation of inhibitors in a sample of 112 patients. Results: 85.71% (96) of the patients suffer from type A hemophilia. Regarding the severity of the disease, the distribution of the patients included in the study was 15 mild (13.39%), 17 moderate (15.18 %) and 80 severe (71.43%). 29.46% (33) of the patients have arthropathies. Regarding the determinants, the dose, the number of applications per week, the black race and the increase in the days of initiation of treatment in relation to the diagnosis maintain a direct relationship with the formation of inhibitors. The age measured in years becomes a protective factor, finally the presence of arthropathies and the type of hemophilia were variables that showed no statistically significant relationship in the formation of inhibitors Conclusions: The formation of inhibitors is highly dose-related, the number of weekly applications, being black increases the probability of forming inhibitors. The strategy of reducing the number of days between diagnosis and the start of treatment would play a fundamental